The Medicines and Healthcare Products Regulatory Agency (MHRA) granted approval for EURneffy, the first intranasal adrenaline (epinephrine) treatment for emergency management of anaphylaxis, offering a needle-free alternative to traditional injectable options.
Anaphylactic shock is considered a very serious case that requires immediate response, as it leads to a sudden drop in blood pressure, which in turn makes it difficult to breathe, putting the patient in a life-threatening position.
Adrenaline has been established for a long period now as a life-saving treatment to counteract the effect of allergic reactions. However, this new dosage form is intended for the use of adults & children weighing 30 kg or above.
Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, highlighted that patient safety is their top priority & they further encourage individuals at risk of severe allergic reactions, as well as those around them, to become well-informed on the appropriate steps to take in the event of an emergency. Guidance and resources are available on the MHRA website to support individuals in being well-prepared.
Moreover, it is advised to carry 2 nasal sprays, & the plunger should be pressed only after the insertion of the product into the nostril in case of requiring a second dose & preventing product loss, respectively.
Finally, anyone who suspects they may be experiencing a side effect from this medicine should seek advice from their doctor, pharmacist, or nurse and report it directly through the MHRA Yellow Card scheme.
